Correction: Identifying barriers to lipoprotein(a) testing in secondary cardiovascular prevention and co-designing implementation strategies: an Italian behavior change wheel-informed study

The author contributions statement was erroneously given as MA: Conceptualization, Writing – review & editing. RM: Conceptualization, Writing – review & editing. APM: Conceptualization, Writing – review & editing. CB: Conceptualization, Writing – review & editing. ES: Conceptualization, Writing – review & editing. FC: Conceptualization, Writing – review & editing. DC: Conceptualization, Writing – review & editing. GL: Conceptualization, Writing – review & editing. FV: Conceptualization, Writing – review & editing. FG: Conceptualization, Writing – review & editing. SC: Conceptualization, Writing – review & editing. DV: Writing – review & editing, Funding acquisition. MC: Funding acquisition, Writing – review & editing. AMG: Formal analysis, Writing – original draft, Writing – review & editing, Conceptualization. SP: Conceptualization, Formal analysis, Writing – original draft, Writing – review & editing. FD: Conceptualization, Formal analysis, Writing – original draft, Writing – review & editing. ALC: Conceptualization, Writing – review & editing.

The correct author contributions statement is MA: Study Design, Data Collection, Writing – review & editing. RM: Study Design, Data Collection, Writing – review & editing. APM: Study Design, Data Collection, Writing – review & editing. CB: Study Design, Data Collection, Writing – review & editing. ES: Study Design, Data Collection, Writing – review & editing. FC: Study Design, Data Collection, Writing – review & editing. DC: Study Design, Data Collection, Writing – review & editing. GL: Study Design, Data Collection, Writing – review & editing. FV: Study Design, Data Collection, Writing – review & editing. FG: Study Design, Data Collection, Writing – review & editing. SC: Study Design, Data Collection, Writing – review & editing. DV: Conceptualization and Study Design, Writing – review & editing. MC: Conceptualization and Study Design, Writing – review & editing. AMG: Conceptualization and Study Design, Data Collection, Formal Analysis, Writing – original draft, Writing – review & editing. SP: Conceptualization and Study Design, Data Collection, Formal Analysis, Writing – original draft, Writing – review & editing. FD: Conceptualization and Study Design, Data Collection, Formal Analysis, Writing – original draft, Writing – review & editing. ALC: Study Design, Data Collection, Writing – review & editing.

An incorrect Funding statement was provided. The Funding statement was erroneously given as “The author(s) declared that financial support was received for this work and/or its publication. This project was funded by Novartis Farma S.p.A. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article, or the decision to submit it for publication.” The correct funding statement reads “The author(s) declared that financial support was received for this work and/or its publication. This project was funded by Novartis Farma S.p.A., Italy.

The conflict of interest statement was erroneously given as “AMG, SP and FD have disclosed that they are employees of IQVIA Solutions SRL. DV and MC are employees of Novartis Farma S.p.A. MA received research funding from Amgen, Amryt, Chiesi, Daiichi Sankyo, Ionis Pharmaceutical, Lilly, Novartis, Pfizer, Regeneron, Sanofi, Ultragenyx, and honoraria for advisory boards, consultancy or speaker bureau from Amarin, Amgen, Amryt, Chiesi, Daiichi Sankyo, Ionis Pharmaceutical, Novartis, Regeneron, Sanofi, Ultragenyx, Viatris. RM received lecture fees from Amgen, Sanofi, Daiichi Sankyo, Novartis. APM received personal fees for the participation in committees of studies sponsored by Bayer, Sanofi, Novartis, AstraZeneca, outside the present work. CB received lectures’ honoraria and consulting fees from: Amgen, Sanofi, Novartis, Daiichi, PIAM, Neopharmed, Amarin, Menarini, Servier, DOC generici, Novo Nordisk, Lilly. GL reports receiving personal fees for scientific speaking and advisory activities from AstraZeneca, Boehringer Ingelheim, Novo Nordisk, Daiichi Sankyo, Sanofi, and Novartis. ALC, in the last three years, has received honoraria, lecture fees or research grants from: Akcea Therapeutics, Amarin, Amgen, Amryt Pharma, AstraZeneca, Daiichi Sankyo, Esperion, Ionis Pharmaceutical, Medscape Education, Menarini, Merck, Mylan, Novartis, Novo Nordisk, PeerVoice, Pfizer, Recordati, Regeneron, Sanofi, The Corpus, Viatris.

The remaining author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.”

The correct conflict of interest statement is “AMG, SP and FD have disclosed that they are employees of IQVIA Solutions SRL. DV and MC have disclosed that they are employees of Novartis Farma S.p.A., Italy. MA received research funding from Amgen, Amryt, Chiesi, Daiichi Sankyo, Ionis Pharmaceutical, Lilly, Novartis, Pfizer, Regeneron, Sanofi, Ultragenyx, and honoraria for advisory boards, consultancy or speaker bureau from Amarin, Amgen, Amryt, Chiesi, Daiichi Sankyo, Ionis Pharmaceutical, Novartis, Regeneron, Sanofi, Ultragenyx, Viatris. RM received lecture fees from Amgen, Sanofi, Daiichi Sankyo, Novartis. APM received personal fees for the participation in committees of studies sponsored by Bayer, Sanofi, Novartis, AstraZeneca, outside the present work. CB received lectures’ honoraria and consulting fees from: Amgen, Sanofi, Novartis, Daiichi, PIAM, Neopharmed, Amarin, Menarini, Servier, DOC generici, Novo Nordisk, Lilly. GL reports receiving personal fees for scientific speaking and advisory activities from AstraZeneca, Boehringer Ingelheim, Novo Nordisk, Daiichi Sankyo, Sanofi, and Novartis. ALC, in the last three years, has received honoraria, lecture fees or research grants from: Akcea Therapeutics, Amarin, Amgen, Amryt Pharma, AstraZeneca, Daiichi Sankyo, Esperion, Ionis Pharmaceutical, Medscape Education, Menarini, Merck, Mylan, Novartis, Novo Nordisk, PeerVoice, Pfizer, Recordati, Regeneron, Sanofi, The Corpus, Viatris.

The authors declare that this study received funding from Novartis S.p.A., Italy. The funder was involved in the study design, interpretation of data, the writing of this article, and the decision to submit it for publication.”

The original version of this article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Footnotes

Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland